Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arcellx Inc (ACLX)

Arcellx Inc (ACLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,978,223
  • Shares Outstanding, K 57,823
  • Annual Sales, $ 107,940 K
  • Annual Income, $ -107,350 K
  • EBIT $ -243 M
  • EBITDA $ -253 M
  • 60-Month Beta 0.36
  • Price/Sales 106.13
  • Price/Cash Flow N/A
  • Price/Book 8.56

Options Overview Details

View History
  • Implied Volatility 65.50% (+7.03%)
  • Historical Volatility 37.94%
  • IV Percentile 87%
  • IV Rank 57.67%
  • IV High 85.06% on 05/14/25
  • IV Low 38.85% on 08/15/25
  • Expected Move (DTE 10) 7.10 (10.59%)
  • Put/Call Vol Ratio 22.08
  • Today's Volume 554
  • Volume Avg (30-Day) 222
  • Put/Call OI Ratio 1.67
  • Today's Open Interest 7,309
  • Open Int (30-Day) 5,811
  • Expected Range 59.89 to 74.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.01
  • Number of Estimates 9
  • High Estimate -0.69
  • Low Estimate -1.19
  • Prior Year -0.87
  • Growth Rate Est. (year over year) -16.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
63.33 +5.75%
on 01/12/26
76.50 -12.46%
on 01/20/26
+0.70 (+1.06%)
since 01/09/26
3-Month
60.35 +10.96%
on 01/05/26
93.24 -28.17%
on 11/17/25
-18.72 (-21.85%)
since 11/10/25
52-Week
47.86 +39.93%
on 05/07/25
94.07 -28.81%
on 10/16/25
-0.03 (-0.04%)
since 02/10/25

Most Recent Stories

More News
Arcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel’s D-Domain Binder

-- CAR constructs representative of anito-cel (D-Domain), cilta-cel (dual VHH), and ide-cel (scFv) were assessed preclinically for tonic signaling and off-target Claudin binding -- ...

ACLX : 66.55 (-3.27%)
Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings

-- The D-Domain binder has a fast off-rate and contributes to anito-cel’s differentiated pharmacology profile in multiple myeloma -- -- A simulation model of CAR T use...

ACLX : 66.55 (-3.27%)
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

-- Anito-cel demonstrated 96% ORR and 74% CR/sCR at a median follow-up of 15.9 months; responses continue to deepen over time -- -- Overall MRD negativity was...

ACLX : 66.55 (-3.27%)
Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition

Saturday, December 6, 2025 at 8:00 p.m. ET

ACLX : 66.55 (-3.27%)
Arcellx Provides Third Quarter 2025 Financial Results

 

ACLX : 66.55 (-3.27%)
Arcellx to Present New Data for Its iMMagine-1 Study and Continues Scientific Momentum with Multiple Presentations at the 67th ASH Annual Meeting and Exposition

-- A more recent data cut will be shared during an oral presentation for the iMMagine-1 study -- -- To date, no delayed neurotoxicities, including no Parkinsonism, no...

ACLX : 66.55 (-3.27%)
Arcellx Inc (ACLX) Has a New Rating from Stifel Nicolaus

Arcellx Inc received a Buy rating and a $129.00 price target from Stifel Nicolaus analyst Stephen Willey today. The company’s shares closed yesterday at $92.37.Elevate Your Investing Strategy: Take advantage...

ACLX : 66.55 (-3.27%)
Canaccord Genuity Keeps Their Buy Rating on Arcellx Inc (ACLX)

Canaccord Genuity analyst John Newman maintained a Buy rating on Arcellx Inc today and set a price target of $121.00. The company’s shares closed yesterday at $87.33.Elevate Your Investing Strategy:...

ACLX : 66.55 (-3.27%)
Arcellx Inc (ACLX) Receives a Hold from Cantor Fitzgerald

In a report released today, Eric Schmidt FCA from Cantor Fitzgerald maintained a Hold rating on Arcellx Inc. The company’s shares closed yesterday at $88.29.Elevate Your Investing Strategy: Take advantage...

ACLX : 66.55 (-3.27%)
Bank of America Securities Keeps Their Buy Rating on Arcellx Inc (ACLX)

Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Arcellx Inc today and set a price target of $112.00. The company’s shares closed yesterday at $82.24.Elevate Your Investing...

ACLX : 66.55 (-3.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Arcellx Inc. is a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx Inc. is based in GAITHERSBURG, Md.

See More

Key Turning Points

3rd Resistance Point 71.61
2nd Resistance Point 70.29
1st Resistance Point 69.55
Last Price 66.55
1st Support Level 67.49
2nd Support Level 66.17
3rd Support Level 65.43

See More

52-Week High 94.07
Fibonacci 61.8% 76.42
Fibonacci 50% 70.97
Last Price 66.55
Fibonacci 38.2% 65.51
52-Week Low 47.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar